摘要
观察持续皮下胰岛素注射治疗(CSII)2型糖尿病。在给予短效胰岛素(Novolin R,42例)和给予人胰岛素类似物Insulin Aspart(46例)的5 d治疗中,2组在血糖控制上差异无统计学意义,InsulinAspart用量明显少于Novolin R。在CSII治疗2型糖尿病中,Insulin Aspart与Novolin R均安全有效,InsulinAspart用量少,优于Novolin R。
The effect of continuous subcutaneous insulin injection (CSII) treatment in type 2 diabetic patients was observed. Forty-six cases and 42 cases were treated with Insulin Aspart (human insulin analogue) and Novolin R (human insulin) for 5 days, respectively. There was no difference in controlling blood glucose between two groups. Both Novolin R and Insulin Aspart during CSII treatment in type 2 diabetes were safe and efficient. The doses of Insulin Aspart were significantly lower than those of Novolin R, thus, it seems that the former was more efficient than the latter.
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
2005年第3期278-279,共2页
Chinese Journal of Endocrinology and Metabolism
